Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective

Trovik, Jone; Mauland, Karen Klepsland; Werner, Henrica M.J.; Wik, Elisabeth; Helland, Harald; Salvesen, Helga B.

doi:10.1016/j.ygyno.2012.01.050

Cited by 17 publications

(16 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Main treatment changes included increase in adjuvant chemotherapy from 0% through 3-9% and a dramatic reduction in adjuvant radiotherapy from 75% through 48-12% (all p<0.001). 5-year disease-specific survival increased significantly during this 30-year period, from 75.8 through 80.2-86.9% (p=0.002) and overall survival from 67.8 through 71.7 to 77.8% (p=0.03) (Trovik et al, 2012). In the present study, the 5-year OS was 92% which was better than both the studies reported here.…”

Section: Discussioncontrasting

confidence: 53%

“…To investigate how changes in therapeutic strategies during a 30-year period are reflected in survival changes through careful characterization of a populationbased series of 1077 endometrial carcinoma patients from Hordaland County, Norway, was undertaken (Trovik et al, 2012). In concordance with increase in endometrial cancer nationally, the number of patients treated from Hordaland County rose from 286 (1981-1990) through 307 (1991-2000) to 484 (2001-2010).…”

Section: Discussionmentioning

confidence: 99%

“…In a study to investigate changes in therapeutic strategies during a 30-year period, reflected survival rate changes through careful characterization of a population-based series of 1077 endometrial carcinoma patients from Hordaland County, Norway (Trovik, 2012). Overall survival increased from 67.8 through 71.7-77.8% (p=0.03).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Hospital-based Study of Endometrial Cancer Survival in Mumbai, India

Ganesh¹,

Sushama²,

Rasika³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Endometrial cancer is common in western women, and the rates are very high; however in India, the rates are as low as 4.3 per 100,000 (Delhi). Objective: To estimate the survival of endometrial cancer patients based on age, education, family history, tobacco habit, number of pregnancies, clinical extent of disease and treatment received. Materials and Methods: The present retrospective study was carried out at the Tata Memorial Hospital (TMH), Mumbai, India, between 1999-2002. 310 cases treated in TMH were considered as eligible entrants for the study. Five-year survival rates were estimated using actuarial and loss-adjusted (LAR) methods. Results: The proportions of patients dying above 50 years of age, non-residents and illiterates was higher than their counterparts. 54.8% of patients had some form of treatment before attending TMH. There were only 4.2% tobacco-chewers and only 6.1% had a family history of cancer. There were 25.8% who had 3-5 pregnancies (not living children) and 38.1% did not remember the pregnancy history. The 5-year overall survival rate was 92%. The five-year rates indicated better prognosis for those aged less than 50 years (97%), non-tobacco-chewers (94%), with no family history of cancer (93%), with localized disease (93%) and those treated with surgery either alone or as a combination treatment (95%). Conclusions: The present study showed that endometrial cancer patients with localized disease at diagnosis have a good outcome in India. A detailed study will help in understanding the prognostic indicators for survival especially with the newer treatment technologies now available.

show abstract

Section: Discussioncontrasting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hospital-based Study of Endometrial Cancer Survival in Mumbai, India

Ganesh¹,

Sushama²,

Rasika³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…All patients were treated at the Section for Gynecological Cancer, Haukeland University Hospital (Bergen, Norway), a referral hospital for patients in the Western Health Region of Norway including Hordaland County, Bergen, Norway, as previously reported (17). Before extracting DNA and RNA from tumors in the primary investigation series, hematoxylin-stained frozen sections were evaluated to ensure high tumor purity in the available tissue (more than 80% tumor purity for the majority of cases).…”

Section: Patients and Tumor Samplesmentioning

confidence: 99%

High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition

Wik

Birkeland

Trovik

et al. 2013

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Purpose: High Stathmin expression has recently been associated with clinical progress in endometrial cancers. Stathmin protein activity is modulated by phosphorylation, and the Serine38 site is one of four Stathmin phospho-sites. The presence and significance of pStathmin(S38) is largely unknown in human cancers, and we here examined the associations between this marker and tumor cell proliferation, clinicopathologic phenotype, and survival impact in endometrial cancer. A relationship with possible treatment targets was explored by integrated analysis of transcriptional alterations.Experimental Design: Primary endometrial cancers from two independent patient series (n ¼ 518/ n ¼ 286) were analyzed. Biomarkers were assessed by immunohistochemistry, FISH, flow cytometry, DNA oligonucleotide microarray, single-nucleotide polymorphism array, and Sanger sequencing, and related to clinicopathologic annotations and follow-up information.Results: High pStathmin(S38) level was associated with poor prognosis, independent of other features, and correlated to increased tumor cell proliferation as well as high Stathmin levels. On the basis of transcriptional differences between high/low pStathmin(S38) tumors, phosphoinositide 3-kinase (PI3K)/ mTOR/HSP90 were suggested as possible targets in pStathmin(S38)-high cases. High pStathmin(S38) was associated with several PI3K pathway alterations: amplification of the 3q26 region, increased PIK3CA copy number (FISH) and a PI3K activation score (all P < 0.05).Conclusions: High pStathmin(S38) is a novel biomarker of increased tumor cell proliferation and impaired prognosis as reported here for independent cohorts of endometrial cancer and not previously shown in human cancer. Our data support a rationale for further studies exploring effects of drugs inhibiting the PI3K signaling pathway in pStathmin(S38)-high endometrial cancer, including a potential value of pStathmin(S38) in predicting response to PI3K/mTOR/HSP90 inhibitors.

show abstract

“…Žinoma, kad iki 20 % mažos rizikos (pagal minėtus veiksnius) navikų recidyvuoja, ir apie pusė pacienčių, kurioms nustatyti didelės rizikos navikai, pasveiksta (37,38). Reikalingi kiti papildomi biožymenys, galintys padėti ne tik atrinkti pacientes, kurioms reikėtų intensyvesnio gydymo nei šiuo metu standartiškai skiriamas, bet ir leistų išvengti pernelyg intensyvaus gydymo tokioms pacientėms, kurioms ligos recidyvo rizika yra minimali, tuo labiau kad sergančiųjų gimdos kūno vėžiu populiacija dažnai yra vyresnio amžiaus moterys, sergančios gretutinėmis ligomis (40,41). Kita vertus, biožymenys galėtų padėti parinkti sisteminį gydymą ir įvertinti toksinio poveikio riziką.…”

Section: Klinikinė Notch Signalinio Kelio Reikšmė Esant Gimdos Kūno Vunclassified

NOTCH signalinio kelio ir ginekologinių piktybinių navikų sąsaja

Lachej¹,

Dabkevičienė²,

Sasnauskienė³

et al. 2017

AML

View full text Add to dashboard Cite

Vilniaus universitetas, Gamtos mokslų fakultetas, Biochemijos ir molekulinės biologijos katedra 3 Nacionalinis vėžio institutas, Konsultacinė poliklinika 4 Nacionalinis vėžio institutas, Mokslinių tyrimų centrasĮvadas. Organizmo ląstelėse vykstančius procesus kontroliuoja įvairūs signaliniai keliai. Vienas iš jų yra NOTCH signalinis kelias. Nustatyta, kad dalinis NOTCH funkcijos praradimas arba nenormalus NOTCH signalo aktyvinimas susijęs su įvairiais žmogaus vystymosi sutrikimais ir ligomis.Medžiaga ir metodika. Pagrindinis informacijos šaltinis ieš-kant duomenų -PubMed duomenų bazė.Rezultatai. Straipsnyje nagrinėjama onkologinių ligų bei NOTCH signalinio kelio dalyvių sąsaja. NOTCH signalas, vystantis vėžiui, gali veikti dvejopai: kaip onkogenas ir kaip naviko augimo slopiklis. Tikslus tokio poveikio mechanizmas dar nėra žinomas. NOTCH signalinio kelio tyrimai svarbūs siekiant atrasti naujus vėžio gydymo būdus, farmakologiniais ir genetiniais metodais valdant NOTCH signalinį kelią. Šioje apžvalgoje daugiausia dėmesio skiriama ginekologiniams piktybiniams navikams, ypač gimdos kūno vėžiui.Išvados. Pastarųjų metų mokslinių tyrimų duomenys rodo, kad NOTCH signalinis kelias yra neabejotinai svarbus formuojantis gimdos kūno vėžiui, todėl jo komponentai gali būti potencialūs prognoziniai biožymenys ir molekuliniai terapiniai taikiniai. Siekiant patikslinti NOTCH signalinio kelio dalyvių reikšmę bei jų sąveiką su kitų signalinių kelių dalyviais, kurie taip pat gali būti svarbūs formuojantis ir progresuojant gimdos kūno vėžiui, reikalingi tolesni šios srities moksliniai tyrimai. Raktažodžiai: NOTCH signalinis kelias, onkoginekologinės ligos ĮVADASProcesus, kai iš vienos ląstelės susidaro daugialąstis organizmas, reguliuoja darni genų veikla, kurią kontroliuoja įvairūs signaliniai keliai. Vienas svarbus, nulemiantis ląstelės likimą, yra NOTCH signalinis kelias; signalo perdavimas šiuo keliu būdingas evoliuciškai skirtingiems organizmams -nuo jūrų ežio iki žmogaus. Signalas, perduodamas per NOTCH signalinio kelio receptorius ir veikdamas kartu su įvairiais ląstelės komponentais, daro įtaką ląstelės diferenciacijos, proliferacijos ir apoptozės procesams (1-3).Pirmą kartą geną, koduojantį NOTCH signalinio kelio receptorių, paminėjo T. H. Morganas beveik prieš 100 metų darbe "Geno teorija". Jis kryžmini-mo būdu išvedė mutantines "NOTCH" museles su

show abstract

Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective

Cited by 17 publications

References 125 publications

Hospital-based Study of Endometrial Cancer Survival in Mumbai, India

Hospital-based Study of Endometrial Cancer Survival in Mumbai, India

High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition

NOTCH signalinio kelio ir ginekologinių piktybinių navikų sąsaja

Contact Info

Product

Resources

About